Skip to Content
Merck
CN
  • Alterations of urinary metabolite profile in model diabetic nephropathy.

Alterations of urinary metabolite profile in model diabetic nephropathy.

Biochemical and biophysical research communications (2014-12-17)
Donald F Stec, Suwan Wang, Cody Stothers, Josh Avance, Deon Denson, Raymond Harris, Paul Voziyan
ABSTRACT

Countering the diabetes pandemic and consequent complications, such as nephropathy, will require better understanding of disease mechanisms and development of new diagnostic methods. Animal models can be versatile tools in studies of diabetic renal disease when model pathology is relevant to human diabetic nephropathy (DN). Diabetic models using endothelial nitric oxide synthase (eNOS) knock-out mice develop major renal lesions characteristic of human disease. However, it is unknown whether they can also reproduce changes in urinary metabolites found in human DN. We employed Type 1 and Type 2 diabetic mouse models of DN, i.e. STZ-eNOS(-/-) C57BLKS and eNOS(-/-) C57BLKS db/db, with the goal of determining changes in urinary metabolite profile using proton nuclear magnetic resonance (NMR). Six urinary metabolites with significantly lower levels in diabetic compared to control mice have been identified. Specifically, major changes were found in metabolites from tricarboxylic acid (TCA) cycle and aromatic amino acid catabolism including 3-indoxyl sulfate, cis-aconitate, 2-oxoisocaproate, N-phenyl-acetylglycine, 4-hydroxyphenyl acetate, and hippurate. Levels of 4-hydroxyphenyl acetic acid and hippuric acid showed the strongest reverse correlation to albumin-to-creatinine ratio (ACR), which is an indicator of renal damage. Importantly, similar changes in urinary hydroxyphenyl acetate and hippurate were previously reported in human renal disease. We demonstrated that STZ-eNOS(-/-) C57BLKS and eNOS(-/-) C57BLKS db/db mouse models can recapitulate changes in urinary metabolome found in human DN and therefore can be useful new tools in metabolomic studies relevant to human pathology.

MATERIALS
Product Number
Brand
Product Description

Supelco
Glycine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Glycine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hippuric acid, 98%
SAFC
Glycine
Supelco
Glycine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Sigma-Aldrich
Glycine, puriss. p.a., reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance)
Sigma-Aldrich
Glycine, tested according to Ph. Eur.
Sigma-Aldrich
4-Methyl-2-oxovaleric acid, ≥98.0% (T)
Sigma-Aldrich
Glycine, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)
Sigma-Aldrich
Glycine, ACS reagent, ≥98.5%
Sigma-Aldrich
Glycine, BioUltra, Molecular Biology, ≥99.0% (NT)
Sigma-Aldrich
Glycine, 99%, FCC
Sigma-Aldrich
Glycine, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Glycine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
Glycine, BioXtra, ≥99% (titration)
Sigma-Aldrich
Glycine, ReagentPlus®, ≥99% (HPLC)
Supelco
Glycine, analytical standard, for nitrogen determination according to Kjeldahl method
USP
Glycine, United States Pharmacopeia (USP) Reference Standard
Glycine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Glycine, Vetec, reagent grade, 98%
Sigma-Aldrich
Glycine 1 M solution
Sigma-Aldrich
Creatinine, anhydrous, ≥98%
Sigma-Aldrich
Indoxyl sulfate potassium salt
Sigma-Aldrich
Sodium hippurate hydrate, ≥99%
Sigma-Aldrich
Sodium 4-methyl-2-oxovalerate, leucine metabolite
Sigma-Aldrich
Glycine hydrochloride, ≥99% (HPLC)
Supelco
Creatinine, Pharmaceutical Secondary Standard; Certified Reference Material